Impact of the COVID-19 pandemic on the management of chronic heart failure.
Adrenergic beta-1 Receptor Antagonists
/ administration & dosage
Aged
Angiotensin-Converting Enzyme Inhibitors
/ administration & dosage
Bisoprolol
/ administration & dosage
COVID-19
Chronic Disease
Female
Heart Failure
/ diagnosis
Humans
Male
Ramipril
/ administration & dosage
Retrospective Studies
Time Factors
Treatment Outcome
ACE-inhibitors
Heart failure
Specialist nursing
β-blockers
Journal
Reviews in cardiovascular medicine
ISSN: 1530-6550
Titre abrégé: Rev Cardiovasc Med
Pays: Singapore
ID NLM: 100960007
Informations de publication
Date de publication:
30 06 2021
30 06 2021
Historique:
received:
15
03
2021
revised:
10
04
2021
accepted:
20
04
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
22
7
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented challenge. Meeting this has resulted in changes to working practices and the impact on the management of patients with heart failure with reduced ejection fraction (HFrEF) is largely unknown. We performed a retrospective, observational study contrasting patients diagnosed with HFrEF attending specialist heart failure clinics at a UK hospital, whose subsequent period of optimisation of medical therapy was during the COVID-19 pandemic, with patients diagnosed the previous year. The primary outcome was the change in equivalent dosing of ramipril and bisoprolol at 6-months. Secondary outcomes were the number and type of follow-up consultations, hospitalisation for heart failure and all-cause mortality. In total, 60 patients were diagnosed with HFrEF between 1 December 2019 and 30 April 2020, compared to 54 during the same period of the previous year. The absolute number of consultations was higher (390 vs 270;
Identifiants
pubmed: 34258895
pii: 1625013549659-1914570188
doi: 10.31083/j.rcm2202034
doi:
Substances chimiques
Adrenergic beta-1 Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Ramipril
L35JN3I7SJ
Bisoprolol
Y41JS2NL6U
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-276Subventions
Organisme : British Heart Foundation
ID : FS/CRTF/20/24071
Pays : United Kingdom
Informations de copyright
© 2021 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
KKW has received speakers’ fees and honoraria from Medtronic, Cardiac Dimensions, Novartis, Abbott, BMS, Pfizer, Bayer and has received an unconditional research grant from Medtronic. JG has received honoraria from Abbott, Medtronic and Microport and has received an unrestricted research grant from Medtronic. SS is funded by a British Heart Foundation Clinical Research Training Fellowship. None of the other authors have any disclosures.